AbbVie is on the rebound after a sell-off on concerns about the pending FDA decision for a biosimilar drug. Humira and Enbrel are among the top-selling drugs to be copycatted but biosimilars are ...

For two decades, immunology was the golden child of biopharma. Blockbusters like Humira (adalimumab), Enbrel (etanercept) and Remicade (infliximab) dominated the sales charts and funded pipelines ...

About 1.5 million Americans suffer from rheumatoid arthritis, a chronic disease in which the immune system attacks healthy cells, typically around the joints, causing swelling and deformity. Generally ...

(Reuters) - Amgen Inc's version of AbbVie Inc's Humira arthritis drug, the world's top-selling medicine, appears similar in potency and safety to the original product, U.S. Food and Drug ...

Increased uptake of biosimilars on par with the utilization rates of filgrastim biosimilars could have saved Medicare Part D $84 million in 2019. Medicare Part D spending on biologics is growing and ...

Dr. Beth Jonas answers the question: 'Anti-TNF Meds For Rheumatoid Arthritis?' — -- Question: What are anti-tumor necrosis factor (anti-TNF) medications and how are they used to treat rheumatoid ...

LONDON, March 15 (Reuters) - Abbott Laboratories' drug Humira and Enbrel, from Pfizer and Amgen , should be the first choices for treating patients with psoriatic arthritis, Britain's ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. The news that Medicare will begin negotiating pricing with drug companies is ...

Today, Coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. This steep discount might have negative consequences for both AbbVie and Amgen later on this year ...

Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization. What's spooking ...